Comparative Pharmacology
Head-to-head clinical analysis: THEOCLEAR L A 260 versus THEOCLEAR 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOCLEAR L A 260 versus THEOCLEAR 200.
THEOCLEAR L.A.-260 vs THEOCLEAR-200
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Theophylline causes bronchodilation by inhibiting phosphodiesterase, increasing cAMP levels, and antagonizing adenosine receptors.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to bronchodilation. It also acts as an adenosine receptor antagonist and may enhance diaphragmatic contractility.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthmaChronic obstructive pulmonary disease (COPD)
FDA: Treatment of asthma and reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD)
Theophylline (THEOCLEAR L.A.-260) 260 mg orally every 12 hours. Adjust dose based on serum theophylline concentrations to achieve 5-15 mcg/mL.
Theophylline 200 mg orally every 6 hours (extended-release) or as directed by serum theophylline concentrations. Usual adult target: 400-600 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 6-12 hours in adults (range 3-12 hours, prolonged in congestive heart failure, liver disease, and with certain drugs). In neonates, half-life is prolonged (24-36 hours).
Terminal elimination half-life: ~8 hours (range 3–12 hours) in adults; prolonged in hepatic impairment, heart failure, COPD, and neonates. Significantly shorter in smokers (4–6 hours).
Hepatic via CYP1A2, CYP2E1, and CYP3A4; undergoes N-demethylation and oxidation.
Hepatic via CYP1A2, CYP2E1, and CYP3A4. Follows Michaelis-Menten kinetics with dose-dependent metabolism.
Renal elimination of unchanged drug (10%) and hepatic metabolism (90%). Metabolism is primarily via CYP1A2 and CYP3A4, with metabolites excreted in urine (about 80% of the dose) and feces (about 20%).
Renal: ~10% unchanged; Hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination; metabolites (caffeine, 3-methylxanthine, 1-methyluric acid) excreted renally. Fecal excretion negligible.
Approximately 40% bound to plasma proteins, primarily albumin.
~40% bound, primarily to albumin.
Volume of distribution: 0.4-0.5 L/kg, indicating distribution into total body water. Higher Vd in neonates and patients with obesity.
0.3–0.7 L/kg; approx. 0.45 L/kg in adults. Increased Vd in premature infants, cirrhosis, and CHF. Distributes freely into breast milk and across placenta.
Oral bioavailability: 96% to 100% for immediate-release formulations; sustained-release formulations have similar bioavailability but with prolonged absorption.
Oral: 96% (nearly complete). Rectal: variable (70–90%). Intravenous: 100%.
No specific GFR-based dose adjustment recommended; however, monitor serum levels closely in renal impairment (CrCl <30 mL/min) due to potential accumulation of metabolites.
No specific GFR-based dose adjustments are recommended; however, monitor serum theophylline concentrations in patients with renal impairment as clearance may be reduced.
Avoid use in Child-Pugh class C; for Child-Pugh class A or B, reduce dose by 50% and monitor serum concentrations.
Child-Pugh Class A: reduce dose by 50%. Child-Pugh Class B: reduce dose by 75%. Child-Pugh Class C: avoid use or use with extreme caution; monitor serum levels frequently. Dose adjustments should be guided by serum theophylline concentrations.
Children 6 months-9 years: Starting dose 12-14 mg/kg/day orally divided every 4-6 hours (immediate-release) or every 12 hours (sustained-release). Children 9-16 years: 12-14 mg/kg/day (max 900 mg/day) divided every 6-8 hours (immediate-release) or every 12 hours (sustained-release). Adjust to serum level 5-15 mcg/mL.
Initial dose: 5 mg/kg orally every 6 hours (immediate-release) or 10-15 mg/kg/day divided every 12 hours (extended-release). Titrate based on serum theophylline levels (target 5-15 mcg/mL). Maximum dose: 16 mg/kg/day up to 400 mg/day for children 1-9 years; 16 mg/kg/day up to 600 mg/day for children 9-16 years.
Elderly patients (≥60 years): Start at 300 mg/day orally (sustained-release) in divided doses every 12 hours; titrate slowly, monitor serum levels, as clearance is reduced.
Start at lowest effective dose (e.g., 200 mg once daily) and titrate slowly. Monitor serum theophylline concentrations closely due to reduced clearance in elderly. Target serum level: 5-10 mcg/mL.
No FDA black box warning.
None
Monitor serum theophylline levels to avoid toxicity; use with caution in patients with cardiac disease, seizure disorders, hepatic impairment, or COPD exacerbation; may interact with multiple drugs altering clearance.
["Narrow therapeutic index; serum levels must be monitored to avoid toxicity.","Use with caution in patients with peptic ulcer, seizure disorders, or cardiac arrhythmias.","Coadministration with drugs that affect CYP1A2 (e.g., cimetidine, fluoroquinolones, macrolides) can alter theophylline clearance.","May cause tachycardia, palpitations, and central nervous system stimulation."]
Hypersensitivity to theophylline or any component; active seizure disorder not controlled by therapy.
Hypersensitivity to theophylline or any component of the formulation.
Data Pending Review
Data Pending Review
Avoid excessive intake of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may potentiate theophylline's CNS stimulant effects and toxicity. Concurrent ingestion of charcoal-broiled meats may increase theophylline clearance, potentially reducing efficacy. Grapefruit juice has been reported to increase theophylline levels; limit intake. A high-protein diet may increase clearance; maintain consistent dietary habits.
Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it can potentiate side effects. Food does not significantly alter absorption, but take with food if gastrointestinal upset occurs. Charcoal-broiled foods may increase metabolism; maintain consistent intake.
Theophylline is not a major teratogen. First trimester: No increased risk of major malformations based on population data. Second and third trimesters: Use may be associated with transient neonatal toxemia (e.g., jitteriness, tachycardia, vomiting) if maternal levels are high near term. Risk of respiratory distress syndrome or neonatal apnea is theoretical only.
FDA Pregnancy Category C. First trimester: Crosses placenta; limited data suggest no major malformations but fetal tachycardia and jitteriness reported. Second and third trimesters: Risk of neonatal apnea, hypoglycemia, and hypocalcemia due to beta-adrenergic stimulation. Avoid during labor due to risk of maternal tachycardia and fetal distress.
Theophylline is excreted into breast milk (M/P ratio approximately 0.6-0.7). Mean milk concentration is about 60-70% of maternal plasma. Relative infant dose is ~10% of maternal weight-adjusted dose. May cause irritability or insomnia in nursing infants, especially at high maternal doses. Benefits likely outweigh risks for asthma therapy, but monitor infant for signs of theophylline toxicity.
Excreted in breast milk; milk-to-plasma ratio approximately 0.6-0.7. Considered compatible with breastfeeding but monitor infant for irritability, insomnia, and tachycardia. Accumulation may occur in neonates with reduced clearance.
Pregnancy decreases theophylline clearance by 20-40% (especially third trimester). Dose may need reduction by 30-50% to maintain therapeutic levels, with close serum monitoring and adjustment every 2-4 weeks as pregnancy progresses. Smoking cessation (common in pregnancy) further reduces clearance and necessitates dose reduction.
Increase dose by 20-30% in second and third trimesters due to increased clearance and volume of distribution. Monitor levels frequently; postpartum return to prepregnancy dosing within 2 weeks.
Category C
Category C
Theo-24 (theophylline extended-release) has a narrow therapeutic index (5-15 mcg/mL). Monitor serum levels due to significant interindividual variability in clearance. Avoid in patients with active peptic ulcer disease or seizure disorders unless absolutely necessary. Cimetidine, ciprofloxacin, and macrolides increase levels; smoking and rifampin decrease levels. Use with caution in heart failure, hepatic impairment, and elderly due to reduced clearance. For acute exacerbations, consider short-acting beta-agonists first.
Theophylline has a narrow therapeutic index (5-15 mcg/mL); levels >20 mcg/mL increase toxicity risk. Use with caution in patients with hepatic impairment, heart failure, or fever, as clearance is reduced. Cimetidine, ciprofloxacin, and macrolides increase theophylline levels; monitor levels and adjust dose. Smoking induces metabolism; require higher doses. Consider drug interactions with CYP1A2 inhibitors/inducers. Serum theophylline levels should be monitored at steady state and with any change in medication or condition.
Take exactly as prescribed, do not crush or chew extended-release tablets.Avoid sudden discontinuation; may require tapering.Report symptoms of toxicity: nausea, vomiting, insomnia, jitteriness, palpitations, or seizures.Limit caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.Discuss all medications with your doctor, especially antibiotics and heartburn drugs (cimetidine, ciprofloxacin).Do not smoke; smoking increases metabolism and may require dose adjustments.If you miss a dose, take it as soon as remembered unless close to next dose; do not double up.
Take THEOCLEAR-200 exactly as prescribed; do not change dose without consulting your doctor.Do not crush or chew sustained-release tablets; swallow whole.Avoid large amounts of caffeine (coffee, tea, chocolate, cola) as it may increase side effects.Inform your doctor if you experience nausea, vomiting, insomnia, tremors, or rapid heartbeat.Do not smoke or start/stop smoking without telling your doctor, as it affects theophylline levels.Keep all appointments for blood tests to monitor theophylline levels.Store at room temperature away from moisture and heat.